Business Description
Newland Pharmaceutical Co Ltd
ISIN : CNE1000065K2
Share Class Description:
SZSE:301277: Class ACompare
Compare
Traded in other countries / regions
301277.China IPO Date
2022-11-16Description
Newland Pharmaceutical Co Ltd is engaged in the research and development, production and sales of chiral pharmaceutical intermediates.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 363.28 | |||||
| Equity-to-Asset | 0.87 | |||||
| Debt-to-EBITDA | 0.01 | |||||
| Interest Coverage | 1619.19 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 12.73 | |||||
| Beneish M-Score | -1.96 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.7 | |||||
| 3-Year EBITDA Growth Rate | -6.2 | |||||
| 3-Year EPS without NRI Growth Rate | -3.7 | |||||
| 3-Year FCF Growth Rate | 57.6 | |||||
| 3-Year Book Growth Rate | 51.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 84.55 | |||||
| 9-Day RSI | 72.23 | |||||
| 14-Day RSI | 65.52 | |||||
| 6-1 Month Momentum % | -18.7 | |||||
| 12-1 Month Momentum % | -12.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.09 | |||||
| Quick Ratio | 6.9 | |||||
| Cash Ratio | 4.91 | |||||
| Days Inventory | 28.27 | |||||
| Days Sales Outstanding | 64.18 | |||||
| Days Payable | 106.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.37 | |||||
| Dividend Payout Ratio | 0.59 | |||||
| Forward Dividend Yield % | 1.88 | |||||
| 5-Year Yield-on-Cost % | 2.37 | |||||
| 3-Year Average Share Buyback Ratio | -10.1 | |||||
| Shareholder Yield % | 4.25 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 41.26 | |||||
| Operating Margin % | 26.11 | |||||
| Net Margin % | 25.35 | |||||
| FCF Margin % | 21.57 | |||||
| ROE % | 11.74 | |||||
| ROA % | 10.38 | |||||
| ROIC % | 23.52 | |||||
| ROC (Joel Greenblatt) % | 51.25 | |||||
| ROCE % | 12.94 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 25.23 | |||||
| PE Ratio without NRI | 24.93 | |||||
| Price-to-Owner-Earnings | 64.93 | |||||
| PEG Ratio | 1.76 | |||||
| PS Ratio | 6.39 | |||||
| PB Ratio | 2.82 | |||||
| Price-to-Tangible-Book | 2.89 | |||||
| Price-to-Free-Cash-Flow | 30.11 | |||||
| Price-to-Operating-Cash-Flow | 17.75 | |||||
| EV-to-EBIT | 16.54 | |||||
| EV-to-EBITDA | 16.54 | |||||
| EV-to-Revenue | 4.7 | |||||
| EV-to-FCF | 21.79 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.07 | |||||
| Price-to-Graham-Number | 1.79 | |||||
| Price-to-Net-Current-Asset-Value | 4.15 | |||||
| Price-to-Net-Cash | 6.62 | |||||
| Earnings Yield (Greenblatt) % | 6.05 | |||||
| FCF Yield % | 3.38 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Newland Pharmaceutical Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 663.476 | ||
| EPS (TTM) (Â¥) | 0.84 | ||
| Beta | 0 | ||
| Volatility % | 36.66 | ||
| 14-Day RSI | 65.52 | ||
| 14-Day ATR (Â¥) | 0.884345 | ||
| 20-Day SMA (Â¥) | 17.706 | ||
| 12-1 Month Momentum % | -12.95 | ||
| 52-Week Range (Â¥) | 13.02 - 31.48 | ||
| Shares Outstanding (Mil) | 200.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Newland Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Newland Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Newland Pharmaceutical Co Ltd Frequently Asked Questions
What is Newland Pharmaceutical Co Ltd(SZSE:301277)'s stock price today?
The current price of SZSE:301277 is ¥21.19. The 52 week high of SZSE:301277 is ¥31.48 and 52 week low is ¥13.02.
When is next earnings date of Newland Pharmaceutical Co Ltd(SZSE:301277)?
The next earnings date of Newland Pharmaceutical Co Ltd(SZSE:301277) is .
Does Newland Pharmaceutical Co Ltd(SZSE:301277) pay dividends? If so, how much?
The Dividend Yield %  of Newland Pharmaceutical Co Ltd(SZSE:301277) is 2.37% (As of Today), Highest Dividend Payout Ratio of Newland Pharmaceutical Co Ltd(SZSE:301277) was 0.69. The lowest was 0.59. And the median was 0.69. The  Forward Dividend Yield % of Newland Pharmaceutical Co Ltd(SZSE:301277) is 1.88%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers